Switzerland-headquartered Sandoz (SWX: SDZ) has released its Q4 2024 financial results. The firm’s global revenues rose 9% year-on-year (YOY) in constant currencies to USD 10.7 billion during the year. The firm’s performance improved during the year, with Q4 revenues up 9% YOY to USD 2.7 billion.
Sales Breakdown
Generic drugs generated USD 7.5 billion in sales, representing a 2% increase. Biosimilars saw significant growth, with sales reaching USD 2.85 billion after a 30% expansion, making them the main growth driver.
Geographical Performance
Sales in Europe jumped 6% YOY to USD 5.36 billion during the year. In North America, sales surged 15% YOY to USD 2.13 billion. International market sales reached USD 2.56 billion, up 8% YOY.
Product Launches and Pipeline
Last year saw multiple biosimilars launched to the market, including Tyruko (natalizumab biosimilar), which launched in Germany in January, Hyrimoz (adalimumab), which launched in the US in April, and Pyzchiva (ustekinumab), which launched in Europe in July. Sandoz added five assets to its biosimilar pipeline last year, bringing its total to 28 molecules. These include knockoff versions of pembrolizumab and nivolumab, anti-tumor drugs at late stages. The company also boasts around 450 generics in its portfolio.
Future Outlook
More biosimilars are expected to launch this year, including Pyzchiva and Tyruko in the US, and Wyost / Jubbonti (denosumab) in Europe and the US. Net sales are projected to grow by a mid-single-digit percentage in 2025.-Fineline Info & Tech
Leave a Reply